Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC
Metrics: PDF 510 views | HTML 1577 views | ?
Jea-Woon Ryu1,*, Seon-Kyu Kim1,*, Mi-Young Son1,2, Su-Jin Jeon1,2, Jung-Hwa Oh3, Jung Hwa Lim1, Sunwha Cho1, Cho-Rok Jung1,2, Ryuji Hamamoto4, Dae-Soo Kim1,2 and Hyun-Soo Cho1
1Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
2Department of Functional Genomics, Korea University of Science and Technology, Daejeon, Republic of Korea
3Korea Institute of Toxicology(KIT), Daejeon, Republic of Korea
4Division of Molecular Modification and Cancer Biology, National Cancer Center, Tokyo, Japan
*Authors share co-first authorship
Hyun-Soo Cho, email: email@example.com
Dae-Soo Kim, email: firstname.lastname@example.org
Keywords: HCC; PRMT1; prognostic marker
Received: April 14, 2017 Accepted: December 05, 2017 Published: December 14, 2017
Hepatocellular carcinoma (HCC) is a major type of liver cancer caused by the hepatitis B and C viruses, alcohol and exposure to aflatoxin. For HCC treatment, anticancer drugs have been widely used, but drug resistance in advanced HCC is an important problem, resulting in a continuous need for novel therapeutic targets. Therefore, in this study, we established a screening pipeline based on RNA-seq to screen novel therapeutic/prognostic targets in HCC and identified PRMT1 (Protein Arginine Methyltransferase 1). In the prognostic analysis, the overexpression of PRMT1 was clearly associated with poor prognosis in a number of HCC patient cohorts. Moreover, after PRMT1 knockdown, HCC cell lines exhibited cell growth and spheroid formation suppression, an increase in Sub-G1 cells by FACS analysis, and enrichment of the cell cycle pathway via functional enrichment analysis. With these results, we demonstrated that PRMT1 could be a novel prognostic marker and therapeutic target for HCC therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.